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ABSTRACT
Introduction Angiosarcomas constitute approximately 
2% to 3% of all soft tissue sarcomas, are characterised 
by an aggressive clinical behaviour and poor outcome. 
Optimal management of localised angiosarcomas 
consists of complete surgical resection with or without 
radiation. However, due to the infiltrating nature of this 
disease, complete resection is often not possible. Despite 
optimal management, the outcome of patients with 
localised disease remains poor. The role of (neo)adjuvant 
chemotherapy in angiosarcomas remains undefined. The 
aim of this study is to document the outcome of patients 
treated with (neo)adjuvant chemotherapy and assess the 
feasibility of performing a prospective trial by evaluating 
the number of patients treated at sarcoma referral centres.
Methods A retrospective search within participating 
EORTC (European Organisation for Research and Treatment 
of Cancer) sites for patients treated with (neo)adjuvant 
chemotherapy was made. Patients treated between 
January 2007 and January 2016 were included.
Results A total of 15 institutions participated and 86 
patients were evaluable, 43 were treated with neoadjuvant, 
27 with adjuvant chemotherapy and 16 with both. At the 
time of analysis, the median follow- up from diagnosis 
was 4.6 years. Median overall survival (OS) was 4.9 years 
(2.9 N) and the percentage alive at 4 years was 57.9 (45.5 
to 68.4). The median disease- free survival was 1.4 years 
(0.9 to 1.7) and the percentage disease- free at 4 years 
was 26.8% (17.9 to 36.5).
Conclusion The outcome of angiosarcoma patients 
treated with (neo)adjuvant chemotherapy in this case 
series compares favourably with previously published 
data. Due to the aggressive nature of angiosarcoma, a 
prospective trial of neoadjuvant chemotherapy should be 
considered.
INTRODUCTION
Soft tissue sarcomas (STS) are rare tumours 
of mesenchymal origin accounting for about 
1% of all adult cancers, and comprising 
over 50 different histological subtypes.1 
Angiosarcomas account for approximately 
2% to 3% of STS and are characterised 
by an aggressive clinical behaviour.2 They 
are malignant endothelial cell tumours of 
lymphatic or vascular origin and complex 
karyotype. They can affect any anatomical 
site, including the skin and viscera. Although 
they can arise spontaneously, angiosarcomas 
are commonly associated with predisposing 
factors, including chronic lymphoedema, 
radiation therapy and various occupational 
risk factors (arsenic, polyvinylchloride and 
thorium dioxide).3 They may also be linked 
to predisposing syndromes, including Reck-
linghausen’s disease, and Klippel- Trenaunay 
and Maffucci syndromes.
Key questions
What is already known about this subject?
 ► Angiosarcomas comprise 2% to 3% of all soft tissue 
sarcomas, have aggressive clinical behaviour and 
poor outcome
 ► Optimal management of localised disease consists 
of complete surgical resection with or without radia-
tion; however, the outcome remains poor
 ► The role of (neo)adjuvant chemotherapy in angiosar-
comas remains undefined
What does this study add?
 ► This is the largest retrospective series report-
ing on the outcomes of (neo)adjuvant therapy in 
angiosarcomas
 ► Multimodality therapy of localised disease, including 
(neo)adjuvant chemotherapy, may be beneficial for 
angiosarcomas
 ► There is variation in the systemic management of 
angiosarcoma in the neoadjuvant setting across 
Europe and no particular regimen(s) or dose(s) can 
be recommended
How might this impact on clinical practice?
 ► Neoadjuvant chemotherapy should be further ex-
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The mainstay of management of localised disease is 
complete surgical resection with or without (neo)adjuvant 
radiation.4 Complete surgical resection can be difficult 
due to the anatomic location of these tumours and the 
diffuse (frequently multifocal) and infiltrating nature of 
the disease, particularly cutaneous angiosarcomas. Conse-
quently, there may be a role for neoadjuvant approaches 
in treating this subtype, both in terms of downstaging 
primary disease and eradicating micrometastatic disease. 
Some retrospective studies have suggested that adjuvant 
radiation has benefit in the management of localised 
angiosarcomas. Mark and colleagues reported actuarial 
2- year and 5- year disease- free survival (DFS) of 44% and 
24%, respectively, in a series of 67 patients with localised 
angiosarcomas treated between 1955 and 1990.5 Pawlik 
and colleagues reported a median overall survival (OS) 
of 28.4 months in a series of 29 patients with cutaneous 
angiosarcomas treated between 1975 and 2002.6 In addi-
tion, the clinical behaviour of angiosarcomas can vary by 
primary site, and this heterogeneity in clinical behaviour 
can make the interpretation of different studies chal-
lenging.7 These data indicate that the outcome of patients 
with localised disease remains poor, with currently no 
conclusive data demonstrating a survival benefit for adju-
vant chemotherapy in resected angiosarcomas.8
Several systemic therapies have shown activity in locally 
advanced and metastatic angiosarcoma. Retrospective and 
prospective studies of various conventional chemotherapy 
schedules have reported response rates between 18% and 
25% and median progression- free survival (PFS) between 
4 and 7 months.9–11 Similarly, for various tyrosine kinase 
inhibitors, median PFS between 3 and 6.6 months has 
been reported.12–15 There are also a number of prospec-
tive trials currently being conducted: NCT02048722 
(Daily Oral Regorafenib for Chemotherapy- Refractory, 
Metastatic and Locally Advanced Angiosarcoma) is active 
and recruiting, while NCT01462630 (Pazopanib Hydro-
chloride in Treating Patients With Advanced Angiosar-
coma) is active having completed recruitment. Recently, 
the randomised Phase III trial of pazopanib with or 
without the antiendoglin antibody demonstrated no 
difference in PFS and OS between the two arms.16
Responses in angiosarcoma are often of short duration 
and the 5- year OS remains poor, in the order of approx-
imately 31% to 43%7 17 with some reports documenting 
5- year disease- specific survival of 60% and a median OS 
in the advanced setting of 7 months.18 The results of a 
recent randomised trial of neoadjuvant chemotherapy 
have renewed interest in the use of this approach in 
specific STS subtypes.19 With a number of systemic agents 
showing a degree of activity in advanced angiosarcomas, 
there is a rationale for using systemic therapy in localised 
angiosarcoma, as the outcome of patients is poor. There-
fore, the aim of this retrospective study was to document 
the outcome of patients with localised angiosarcoma 
treated with (neo)adjuvant chemotherapy at EORTC 
(European Organisation for Research and Treatment 
of Cancer) centres. A secondary aim was to record the 
number of patients with localised angiosarcoma treated 
to gauge the feasibility of a prospective randomised trial 
of neoadjuvant/adjuvant chemotherapy in this specific 
subtype.
MATERIALS AND METHODS
The EORTC Soft Tissue and Bone Sarcoma Group 
members were sent a questionnaire regarding interest 
in participating in the study. Institutional approval at 
each participating centre was obtained prior to data 
collection. Patients with histologically documented and 
non- metastatic angiosarcoma starting (neo)adjuvant 
treatment between January 2007 and January 2016 were 
included. All patients were 18 years or older. DFS and OS 
were investigated from both the date of diagnosis and 
the date of surgery (only for patients that underwent 
surgery).
The information retrieved included patient and tumour 
characteristics, treatment information and survival data. 
Patients with limited or no information in the required 
fields were excluded. Patients whose (neo)adjuvant treat-
ment started before 1 January 2007 or after 1 January 
2016 were also excluded, as were patients who did not 
receive (neo)adjuvant treatment.
Statistical analysis
Descriptive statistics were used to present patient and 
tumour characteristics as well as treatment- related infor-
mation. Median and range were used for continuous vari-
ables and proportions (%) for categorical variables.
DFS from diagnosis was defined as the time, from 
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relapse (local recurrence or metastasis) or death, which-
ever occurred first. Patients alive and relapse- free at the 
time of the clinical cut- off were censored at the date of 
the last follow- up. OS from diagnosis was defined as the 
time from the date of the first diagnosis to the date of 
death. Patients alive at the time of the clinical cut- off were 
censored at the date of last follow- up. Similar definition 
applies for DFS and OS from the date of surgery.
DFS and OS are displayed using Kaplan- Meier curves. 
Four- year survival estimates and median survival times are 
reported for DFS and OS (from both the date of diag-
nosis and the date of surgery), along with their two- sided 
95% CI.
All statistical analysis was performed using SAS V.9.3.
RESULTS
A total of 15 institutions from nine different countries 
contributed to the patient population (figure 1). Of the 
110 patients considered for the study, three were excluded 
due to limited or no records available, four were excluded 
because their neoadjuvant treatment started before 1 
January 2007 or after 1 January 2016 and 17 due to no 
systemic treatment.
The characteristics for the 86 eligible patients are 
shown in table 1.
The primary site was the breast in 35% of patients, 
and 69.4% of these primary breast angiosarcomas were 
associated with prior radiation. The median tumour size 
was 45 mm (range 1 to 170) and over 46% of patients had 
operable disease at presentation. All tumour characteris-
tics are shown in table 2.
Neoadjuvant chemotherapy followed by surgery was 
the treatment paradigm followed in one- fourth of the 
patients (25.6%). In fewer patients, surgery was combined 
with adjuvant chemotherapy and radiotherapy (16.3%) 
or adjuvant chemotherapy alone (15.1%) or neoadjuvant 
and adjuvant chemotherapy (14%). Table 3 summarises 
the types of administered therapy in operable and locally 
advanced disease at presentation.
Surgery of the primary tumour was performed in 72 out 
of 86 patients (83.7%): in 53 patients (73%) with clear 




Age at diagnosis   
  ≤40 21 (24.4)
  40 to ≤50 6 (7.0)
  50 to ≤70 38 (44.2)
  >70 21 (24.4)
Age
  Median 60.5
  Range 18.0 to 84.0
  N obs 86
Gender
  Male 38 (44.2)
  Female 48 (55.8)
ECOG PS at treatment start
  ECOG PS 0 44 (51.2)
  ECOG PS 1 37 (43.0)
  ECOG PS 2 3 (3.5)
  Missing 2 (2.3)
ECOG, Eastern Cooperative Oncology Group; N obs, number of 
observations; PS, performance status.








N (%) N (%) N (%)
Site of the primary tumour     
  Breast 8 (12.9) 20 (83.3) 28 (32.6)
  Cutaneous/scalp 15 (24.2) 2 (8.3) 17 (19.8)
  Extremities 13 (21.0) 2 (8.3) 15 (17.4)
  Visceral 13 (21.0) 0 (0.0) 13 (15.1)
  Other 13 (21.0) 0 (0.0) 13 (15.1)
Specification of other sites of tumour
  Right atrium 3 (4.8) 0 (0.0) 3 (3.5)
  Maxilla 2 (3.2) 0 (0.0) 2 (2.3)
  Head and neck 1 (1.6) 0 (0.0) 1 (1.2)
  Iliacus muscle with pelvis 
infiltration
1 (1.6) 0 (0.0) 1 (1.2)
  Penis 1 (1.6) 0 (0.0) 1 (1.2)
  Bone (sacrum) 1 (1.6) 0 (0.0) 1 (1.2)
  Retroperitoneum 1 (1.6) 0 (0.0) 1 (1.2)
  Pelvis/perineum 1 (1.6) 0 (0.0) 1 (1.2)
  Bone (basin) 1 (1.6) 0 (0.0) 1 (1.2)
  Abdominal wall, subcutis 1 (1.6) 0 (0.0) 1 (1.2)
  CNS (cerebellum) 1 (1.6) 0 (0.0) 1 (1.2)
Tumour grade according to 
FNCLCC categorisation
1 (1.6) 0 (0.0) 1 (1.2)
  Grade 1 3 (6.5) 0 (0.0) 3 (3.5)
  Grade 2 15 (32.6) 6 (15.0) 21 (24.4)
  Grade 3 25 (54.3) 32 (80.0) 57 (66.3)
  Missing 3 (6.5) 2 (5.0) 5 (5.8)
Dimension
  Median 45.0 42.5 45.0
  Range 8.0 to 170.0 1.0 to 100.0 1.0 to 170.0
  N obs 52 18 70
Tumour extent at presentation
  Locally advanced 34 (54.8) 12 (50.0) 46 (53.5)
  Operable 28 (45.2) 12 (50.0) 40 (46.5)
CNS, central nervous system; FNCLCC, Fédération Nationale des Centers de 
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margins (R0), in 17 (23.6%) with R1 and in 1.4% with R2 
resection. Radiotherapy was administered in 29 patients 
(33.7%); preoperatively in 11 patients (37.9%) and post-
operatively in 18 patients (62.1%).
Neoadjuvant chemotherapy
In a total of 59 patients who received neoadjuvant chemo-
therapy, the median number of cycles administered was 
six (range 1 to 23) with seven patients receiving nine cycles 
or above. Of these seven patients, all received neoadju-
vant chemotherapy until maximum response (defined by 
the individual investigators based on imaging (RECIST) 
or clinical response if clinically assessable disease), except 
for one patient, for whom paclitaxel was withdrawn due 
to disease progression (bone metastasis). The neoadju-
vant chemotherapy regimens used in all 59 patients are 
shown in table 4.
Of the 59 patients, 28 (47.5%) discontinued neoadju-
vant chemotherapy when the scheduled treatment was 
completed, 20 (33.9%) discontinued chemotherapy on 
maximal response, and in the remainder, reasons for 
discontinuation were progressive disease (10.2%), physi-
cian choice (3.4%), adverse events (3.4%) and patient 
refusal (1.7%).
Adjuvant chemotherapy
Out of the 86 patients, 43 (50%) received adjuvant 
chemotherapy with a median number of five cycles (1 to 
26). One patient received a total of 26 cycles of docetaxel 
along with postoperative radiotherapy. Discontinuation 
of treatment was not due to progressive disease, but the 
decision of the treating physician.
The majority of patients (33, 76.7%) completed the 
scheduled treatment, three (7%) discontinued due to 
adverse events, two (4.7%) due to patient’s refusal and 
one (2.3%) due to physician’s choice. Chemotherapy 
comprised primarily taxanes (docetaxel and paclitaxel) 
and gemcitabine (table 5).
Due to missing data no analysis regarding duration of 
chemotherapy was performed.








N (%) N (%) N (%)
Type of treatment
  Neoadjuvant chemotherapy alone 10 (21.7) 0 (0.0) 10 (11.6)
  Neoadjuvant chemotherapy+surgery 13 (28.3) 9 (22.5) 22 (25.6)
  Neoadjuvant chemotherapy+radiotherapy* 4 (8.7) 0 (0.0) 4 (4.7)
  Surgery+adjuvant chemotherapy 2 (4.3) 11 (27.5) 13 (15.1)
  Neoadjuvant chemotherapy+surgery+adjuvant chemotherapy 6 (13.0) 6 (15.0) 12 (14.0)
  Neoadjuvant chemotherapy+radiotherapy+surgery* 3 (6.5) 1 (2.5) 4 (4.7)
  Neoadjuvant chemotherapy+surgery+radiotherapy 3 (6.5) 0 (0.0) 3 (3.5)
  Surgery+radiotherapy+adjuvant chemotherapy* 4 (8.7) 10 (25.0) 14 (16.3)
  Neoadjuvant chemotherapy+radiotherapy+surgery+adjuvant 
chemotherapy*
0 (0.0) 3 (7.5) 3 (3.5)
  Neoadjuvant chemotherapy+surgery+radiotherapy+adjuvant 
chemotherapy*
1 (2.2) 0 (0.0) 1 (1.2)
*Information on whether radiotherapy was administered concomitantly with (neo)adjuvant chemotherapy was not consistently collected.





  Paclitaxel 21 (35.6)
  Doxorubicin+ifosfamide 7 (11.9)
  Gemcitabine+docetaxel 6 (10.2)
  Docetaxel 5 (8.5)
  Gemcitabine 5 (8.5)
  Doxorubicin+paclitaxel 2 (3.4)
  Etoposide+doxorubicin+ifosfamide 2 (3.4)
  Ifosfamide 2 (3.4)
  Sofarenib 2 (3.4)
  Cyclophosphamide+doxorubicin+dacarbazine 1 (1.7)
  Docetaxel+doxorubicin 1 (1.7)
  Doxorubicin 1 (1.7)
  Gemcitabine+docetaxel+doxorubicin+ifosfamide 1 (1.7)
  Gemcitabine+doxorubicin+ifosfamide 1 (1.7)
  Gemcitabine+paclitaxel 1 (1.7)
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Subsequent treatments following relapse
Fifty- eight patients eligible for DFS experienced a relapse, 
out of 85. For 27 patients (45.5%), subsequent treatment 
comprised of systemic therapy alone and for four (6.9%) 
surgery alone. Nineteen patients had different combi-
nations of treatment while eight (13.8%) had no subse-
quent therapy at all.
A total of 13 (22.4%) patients had subsequent surgery 
and 10 (17.2%) had subsequent radiotherapy.
Efficacy
At the time of the analysis, the overall median follow- up 
from diagnosis was 4.6 years (IQR: 2.9 to 7.1) and from 
surgery was 4.3 years (IQR: 2.7 to 6.9). Over 55% were 
alive from diagnosis at their last follow- up date, while 
disease progression was the cause of death in 92.1% of 
patients (table 6A). Similar results were observed from 
the date of surgery, with 59.7% patients being alive from 
surgery at their last follow- up date, while disease progres-
sion was the cause of death in 89.7% (table 6B).
Eighty- five patients were eligible for analyses of DFS 
and OS from the date of diagnosis. Seventy- two patients 
(who were event- free at the time of surgery) were eligible 
for analyses of DFS and OS from the date of surgery.
DFS and OS from date of diagnosis
The median DFS was 1.4 years (95% CI, 0.9 to 1.7) and 
4- year DFS was 26.8% (95% CI, 17.9 to 36.5) figure 2A. 
The median OS was 4.9 years (95% CI, 2.9 n) and 4- year 
OS was 57.9% (95% CI, 45.5 to 68.4) figure 2B.
DFS and OS from date of surgery
The median DFS was 1 year (95% CI, 0.7 to 1.6) and 
4- year DFS was 29.9% (95% CI, 19.8 to 40.7) (figure 3A). 
The median OS was 5.1 years (95% CI, 3.2 n) and 4- year 
OS was 63% (95% CI, 49.3 to 17.9) (figure 3B).
DISCUSSION
Angiosarcomas constitute a rare but aggressive STS 
subtype. Complete surgical resection provides the best 
chance of cure for localised disease. However, despite 
optimal surgical resection, recurrence rates are high, 
and the outcome remains poor. The aggressive nature of 
angiosarcomas and the limited options available to treat 
metastatic disease indicate a potential role for (neo)adju-
vant chemotherapy in this sarcoma subtype.
To our knowledge, this multi- institutional study represents 
the largest retrospective series published to date, presenting 
the outcomes of neoadjuvant and adjuvant chemotherapy 
in patients with angiosarcomas.20 21 Our study highlights the 
clinical heterogeneity of angiosarcomas and also the varia-
tion in management between high volume EORTC sarcoma 
centres. A variety of chemotherapy regimens were used in 
this cohort but the most commonly used were paclitaxel 
(36%) or the combination of gemcitabine with docetaxel 
(13.9%) in line with drug efficacy data demonstrated in 
prospective Phase II studies, although in advanced/meta-
static disease.9 21 In addition brivanib, a selective inhibitor 
of vascular endothelial growth factor and fibroblast growth 
factor signalling, has shown some activity in angiosarcoma.22 
The variation in therapeutic approaches used for localised 
(locally advanced or operable) disease is not surprising, 
given the absence of prospective randomised controlled 
data, and consequently, the lack of evidence- based recom-
mendations on the neoadjuvant/adjuvant therapy of 





  Paclitaxel 12 (27.9)
  Doxorubicin+ifosfamide 6 (14.0)
  Gemcitabine+docetaxel 6 (14.0)
  Gemcitabine+docetaxel+doxorubicin+ifosfamide 5 (11.6)
  Doxorubicin 3 (7.0)
  Gemcitabine 2 (4.7)
  Cisplatin 2 (4.6)
  Docetaxel 1 (2.3)
  Ifosfamide 1 (2.3)
  Caelyx 1 (2.3)
  Epirubicine 1 (2.3)
  Temozolomide 1 (2.3)
  Vincristine+dacarbazine 1 (2.3)
  Vinorelbine 1 (2.3)
Table 6 (A) Reason of death from diagnosis and (B) Reason 
of death from surgery




Cause of death   
  Progression of disease 35 (92.1)
  Both progression of disease and toxicity 
indistinguishable
1 (2.6)
  Wound complications 1 (2.6)
  Missing 1 (2.6)




Cause of death   
  Progression of disease 34 (87.2)
  Both progression of disease and toxicity 
indistinguishable
1 (2.6)
  Cardiac problem 1 (2.6)
  Wound complications 1 (2.6)
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angiosarcoma. This presents an opportunity for research 
collaboration and also the development of consensus guide-
lines for the management of vascular sarcomas.
To our knowledge, this multi- institutional study 
represents the largest retrospective series published to 
date, presenting the outcomes of neoadjuvant and adju-
vant chemotherapy in patients with angiosarcomas.20 21 
Our study highlights the clinical heterogeneity of angiosar-
comas and also the variation in management between high 
volume EORTC sarcoma centres. A variety of chemotherapy 
regimens were used in this cohort but the most commonly 
used were paclitaxel (36%) or the combination of gemcit-
abine with docetaxel (13.9%) in line with drug efficacy data 
demonstrated in prospective Phase II studies, although in 
advanced/metastatic disease.9 21 The variation in thera-
peutic approaches used for localised (locally advanced or 
operable) disease is not surprising, given the absence of 
prospective randomised controlled data, and consequently, 
the lack of evidence- based recommendations on the neoad-
juvant/adjuvant therapy of angiosarcoma. This presents an 
opportunity for research collaboration and also the devel-
opment of consensus guidelines for the management of 
vascular sarcomas.
The limitations of small size and retrospective studies 
are acknowledged. As the different treatment modalities 
are not allocated randomly, establishing causal effects 
between treatment allocation and outcome is not possible: 
it is likely that the association found may be explained by 
confounding factors (eg, patients with worse prognosis 
receiving more intensive regimens). Making unbiased treat-
ment modality comparisons would require a larger sample 
size, as well as complete knowledge and collection of all 
factors linked to both treatment modalities and outcome. 
As a result, subgroup analyses were not performed, due to 
the heterogeneity of tumour characteristics and the varia-
tion of treatment approaches.
CONCLUSION
This is the largest retrospective series reporting on 
the outcomes of neoadjuvant/adjuvant therapy in 
Figure 2 (A) DFS from diagnosis. (B) OS from diagnosis. 
DFS, disease- free survival; OS, overall survival.
Figure 3 (A) DFS from surgery. (B) OS from surgery. DFS, 
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angiosarcomas. The major challenges encountered in this 
study are the heterogeneity of angiosarcomas and conse-
quently the variation in practice across sarcoma centres 
in Europe. This presents considerable challenges in the 
design of clinical trials in angiosarcomas, particularly in 
the localised disease setting. Given the aggressive clinical 
behaviour of this disease and poor outcome, collaborative 
efforts should focus on approaches and treatment modal-
ities that can improve survival. Multimodality therapy of 
localised disease including neoadjuvant/adjuvant chemo-
therapy could be further explored in the context of a 
prospective randomised controlled clinical trial.
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